Imed19-Privat

At Imed19-Privat in Vienna, clinical research focuses on cardiovascular diseases, nutritional and metabolic diseases, and metabolism. The studies are centered on major conditions such as atherosclerotic cardiovascular disease, calcific aortic valve stenosis, and elevated Lp(a), with an emphasis on testing new approaches to reduce heart-related risk and slow disease progression.

• Studies in cardiovascular disease are evaluating whether new treatments can lower the risk of major heart events and improve long-term outcomes.
• Research in metabolic disease includes efforts to support weight reduction and better control of type 2 diabetes.
• Kidney-related research is also included, particularly for people with chronic kidney disease and albuminuria.

Overall, the site is exploring therapies that aim to improve heart, kidney, and metabolic health in patients with overlapping chronic conditions.

Clinical trials at Imed19 Privat also address the connection between chronic kidney disease, diabetes mellitus type 2, and broader cardiometabolic risk. These studies are designed to test whether new treatment combinations can improve kidney protection while also reducing cardiovascular complications.

• Research is examining therapies for albuminuria and kidney decline in people with chronic kidney disease.
• Several trials focus on people with type 2 diabetes who also have elevated cardiovascular risk.
• The goal is to find better ways to prevent hospitalization, worsening kidney function, and heart-related events.

This makes the site a relevant center for studies linking kidney health with broader metabolic and cardiovascular outcomes.

The site is involved in studies of obesity, overweight, and abnormal lipid-related risk, including elevated lipoprotein(a). These trials are exploring whether new therapies can support weight loss, improve metabolic health, and reduce the chance of serious cardiovascular events.

• Trials in obesity and overweight are assessing support for healthier body weight and better diabetes control.
• Lipid-focused research is looking at ways to lower Lp(a) and reduce heart disease risk.
• The research aims to improve prevention for people with combined metabolic and cardiovascular risk factors.

Together, these studies reflect a strong interest in prevention-oriented care for patients with weight, lipid, and heart-related conditions.